Interventions that induce modifications in the tumor microenvironment

Cancer/Radiotherapie

Volumn 15, Issue 5, 2011, Pages 376-382

  Bernhard, E J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Cell signaling; Hypoxia; Stem cells; Tumor stroma; Vasculogenesis

Indexed keywords

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; HUMAN; HYPOXIA; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL HYPOXIA; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; CYSTEINE; CYTOTOXINS; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR MATRIX; GENE THERAPY; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOSELENIUM COMPOUNDS; RADIATION TOLERANCE; RADIOTHERAPY; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 79961211009     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2011.01.007     Document Type: Review

References (101)

1. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99:1441-1454.
2. Maity A., Bernhard E.J. Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy. Cancer Res 2010, 70:2141-2145.
3. Chiche J., Brahimi-Horn M.C., Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med 2010, 14:771-794.
4. Mohyeldin A., Garzon-Muvdi T., Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010, 7:150-161.
5. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379:88-91.
6. Horsman M., Wouters B., Joiner M., Overgaard J. The oxygen effect and fractionated radiotherapy. Basic clinical radiobiology 2009, 207-216. Hodder Arnold, London. J.V.D. Kogel (Ed.).
7. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
8. Gerweck L.E., Vijayappa S., Kurimasa A., Ogawa K., Chen D.J. Tumor cell radiosensitivity is a major determinant of tumor response to radiation. Cancer Res 2006, 66:8352-8355.
9. Ogawa K., Boucher Y., Kashiwagi S., Fukumura D., Chen D., Gerweck L.E. Influence of tumor cell and stroma sensitivity on tumor response to radiation. Cancer Res 2007, 67:4016-4021.
10. Budach W., Taghian A., Freeman J., Gioioso D., Suit H.D. Impact of stromal sensitivity on radiation response of tumors. J Natl Cancer Inst 1993, 85:988-993.
11. Garcia-Barros M., Thin T.H., Maj J., Cordon-Cardo C., Haimovitz-Friedman A., Fuks Z., et al. Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited. Cancer Res 2010, 70:8179-8186.
12. Sofia Vala I., Martins L.R., Imaizumi N., Nunes R.J., Rino J., Kuonen F., et al. Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One 2010, 5:e11222.
13. John-Aryankalayil M., Palayoor S.T., Cerna D., Simone C.B., Falduto M.T., Magnuson S.R., et al. Fractionated radiation therapy can induce a molecular profile for therapeutic targeting. Radiat Res 2010, 174:446-458.
14. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
15. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953, 26:638-648.
16. Brizel D.M., Dodge R.K., Clough R.W., Dewhirst M.W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999, 53:113-117.
17. Fyles A.W., Milosevic M., Pintilie M., Hill R.P. Cervix cancer oxygenation measured following external radiation therapy. Int J Radiat Oncol Biol Phys 1998, 42:751-753.
18. Nordsmark M., Bentzen S.M., Rudat V., Brizel D., Lartigau E., Stadler P., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77:18-24.
19. Kovacic P., Osuna J.A. Mechanisms of anti-cancer agents: emphasis on oxidative stress and electron transfer. Curr Pharm Des 2000, 6:277-309.
20. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56:4509-4515.
21. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996, 56:941-943.
22. Freiberg R.A., Krieg A.J., Giaccia A.J., Hammond E.M. Checking in on hypoxia/reoxygenation. Cell Cycle 2006, 5:1304-1307.
23. Martinive P., Defresne F., Quaghebeur E., Daneau G., Crokart N., Grégoire V., et al. Impact of cyclic hypoxia on HIF-1alpha regulation in endothelial cells: new insights for anti-tumor treatments. FEBS J 2009, 276:509-518.
24. Daneau G., Boidot R., Martinive P., Feron O. Identification of cyclooxygenase-2 as a major actor of the transcriptomic adaptation of endothelial and tumor cells to cyclic hypoxia: effect on angiogenesis and metastases. Clin Cancer Res 2010, 16:410-419.
25. Lin Z., Mechalakos J., Nehmeh S., Schoder H., Lee N., Humm J., et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 2008, 70:1219-1228.
26. Bennett M, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev 2005:CD005007.
27. Brown J.M. Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys 2001, 49:319-326.
28. Wang J., Biedermann K.A., Brown J.M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res 1992, 52:4473-4477.
29. Lloyd R.V., Duling D.R., Rumyantseva G.V., Mason R.P., Bridson P.K. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol 1991, 40:440-445.
30. Rischin D., Peters L.J., O'Sullivan B., Giralt J., Fisher R., Yuen K., et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010, 28:2989-2995.
31. Peters L.J., O'Sullivan B., Giralt J., Fitzgerald T.J., Trotti A., Bernier J., et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2010, 28:2996-3001.
32. Hicks K.O., Siim B.G., Jaiswal J.K., Pruijn F.B., Fraser A.M., Patel R., et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res 2010, 16:4946-4957.
33. Lunt S.J., Cawthorne C., Ali M., Telfer B.A., Babur M., Smigova A., et al. The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy. Br J Cancer 2010, 103:201-208.
34. Overgaard J., Hansen H.S., Overgaard M., Bastholt L., Berthelsen A., Specht L., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998, 46:135-146.
35. Overgaard J., Eriksen J.G., Nordsmark M., Alsner J., Horsman M.R. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005, 6:757-764.
36. Sun X, Niu G, Chan N, Shen B, Chen X. Tumor hypoxia imaging. Mol Imaging Biol 2010; [Epub ahead of print September 14]. doi:10.1007/s11307-010-0420-z.
37. Carmeliet P., De Smet F., Loges S., Mazzone M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 2009, 6:315-326.
38. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
39. Ahn G.O., Brown J.M. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis 2009, 12:159-164.
40. Hendrix M.J., Seftor E.A., Hess A.R., Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003, 3:411-421.
41. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468(7325):829-33. Epub 2010 November 21.
42. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:829-833.
43. Gorski D.H., Beckett M.A., Jaskowiak N.T., Calvin D.P., Mauceri H.J., Salloum R.M., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999, 59:3374-3378.
44. Hess C., Vuong V., Hegyi I., Riesterer O., Wood J., Fabbro D., et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 2001, 85:2010-2016.
45. Crane C.H., Eng C., Feig B.W., Das P., Skibber J.M., Chang G.J., et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010, 76:824-830.
46. Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, et al. Phase II Study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2010: [Epub ahead of print October 5]. doi:10.1016/j.ijrobp.2010.07.024.
47. Spigel D, Hainsworth J., Yardley D., Raefsky E., Patton J., Peacock N., et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010, 28:43-48.
48. Ocaña A., Amir E., Vera F., Eisenhauer E.A., Tannock I.F. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011, 29:254-256.
49. Eskens F.A., Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006, 42:3127-3139.
50. Verheul H.M., Pinedo H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007, 7:475-485.
51. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
52. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731-3736.
53. Sorensen A.G., Batchelor T.T., Zhang W.T., Chen P.J., Yeo P., Wang M., et al. A " vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009, 69:5296-5300.
54. Horsman M.R., Siemann D.W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006, 66:11520-11539.
55. Qayum N., Muschel R.J., Im J.H., Balathasan L., Koch C.J., Patel S., et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 2009, 69:6347-6354.
56. Cerniglia G.J., Pore N., Tsai J.H., Schultz S., Mick R., Choe R., et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 2009, 4:e6539.
57. Alghisi G.C., Ponsonnet L., Ruegg C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One [Electronic Resource] 2009, 4:e4449.
58. Bhattacharya A., Seshadri M., Oven S.D., Toth K., Vaughan M.M., Rustum Y.M. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin Cancer Res 2008, 14:3926-3932.
59. Berggren M., Gallegos A., Gasdaska J., Powis G. Cellular thioredoxin reductase activity is regulated by selenium. Anticancer Res 1997, 17:3377-3380.
60. Kashiwagi S., Tsukada K., Xu L., Miyazaki J., Kozin S.V., Tyrrell J.A., et al. Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med 2008, 14:255-257.
61. Mazzone M., Dettori D., Leite de Oliveira R., Loges S., Schmidt T., Jonckx B., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
62. Korc M. Pancreatic cancer-associated stroma production. Am J Surg 2007, 194:S84-S86.
63. Spector I.H., Kawada H., Nagler N., Genin A., Pines O.M. Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development. Pancreas 2010, 39:1008-1015.
64. Medicherla S.L.L., Ma J.Y., Kapoun A.M., Gaspar N.J., Liu Y.W., Mangadu R., et al. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. Anticancer Res 2007, 27:4149-4157.
65. Shimizu K. Mechanisms of pancreatic fibrosis and applications to the treatment of chronic pancreatitis. J Gastroenterol 2008, 43:823-832.
66. Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE. Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res 2010;70(21):8319-28.
67. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
68. Butcher D.T., Alliston T., Weaver V.M. A tense situation: forcing tumour progression. Nat Rev Cancer 2009, 9:108-122.
69. Rofstad E.K., Ruud E.B., Mathiesen B., Galappathi K. Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue. Clin Cancer Res 2010, 16:936-945.
70. Patenaude A., Parker J., Karsan A. Involvement of endothelial progenitor cells in tumor vascularization. Microvasc Res 2010, 79:217-223.
71. Ahn G.O., Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13:193-205.
72. Lerman O.G., Singh M.R., Thanik S.P., Chang V.D., Seiser C.C., Brown N., et al. Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and -independent SDF-1 induction. Blood 2010, 116:3669-3676.
73. Ahn G.O., Tseng D., Liao C.H., Dorie M.J., Czechowicz A., Brown J.M. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A 2010, 107:8363-8368.
74. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010, 120:694-705.
75. McKeage M.J., Baguley B.C. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010, 116:1859-1871.
76. Pili R., Rosenthal M.A., Mainwaring P.N., Van Hazel G., Srinivas S., Dreicer R., et al. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 2010, 16:2906-2914.
77. Rustin G.J., Shreeves G., Nathan P.D., Gaya A., Ganesan T.S., Wang D., et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010, 102:1355-1360.
78. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461. [see comment].
79. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
80. Dechantsreiter M.A., Planker E., Matha B., Lohof E., Holzemann G., Jonczyk A., et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999, 42:3033-3040.
81. Oliveira-Ferrer L., Hauschild J., Fiedler W., Bokemeyer C., Nippgen J., Celik I., et al. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 2008, 27:86.
82. Reardon D.A., Fink K.L., Mikkelsen T., Cloughesy T.F., O'Neill A., Plotkin S., et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008, 26:5610-5617.
83. Burke P.A., DeNardo S.J., Miers L.A., Lamborn K.R., Matzku S., DeNardo G.L. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002, 62:4263-4272.
84. Albert J.M., Cao C., Geng L., Leavitt L., Hallahan D.E., Lu B. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 2006, 65:1536-1543.
85. Mikkelsen T., Brodie C., Finniss S., Berens M.E., Rennert J.L., Nelson K., et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 2009, 124:2719-2727.
86. Reynolds A.R., Hart I.R., Watson A.R., Welti J.C., Silva R.G., Robinson S.D., et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009, 15:392-400.
87. Patsenker E., Popov Y., Stickel F., Schneider V., Ledermann M., et al. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009, 50:1501-1511.
88. Stupp R., Hegi M.E., Neyns B., Goldbrunner R., Schlegel U., Clement P.M., et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010, 28:2712-2718.
89. Grossman S.A., Ye X., Piantadosi S., Desideri S., Nabors L.B., Rosenfeld M., et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010, 16:2443-2449.
90. El Hallani S., Boisselier B., Peglion F., Rousseau A., Colin C., Idbaih A., et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 2010, 133:973-982.
91. Tentori L., Dorio A.S., Muzi A., Lacal P.M., Ruffini F., Navarra P., et al. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 2008, 19:1039-1043.
92. Friess H., Langrehr J.M., Oettle H., Raedle J., Niedergethmann M., Dittrich C., et al. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 2006, 6:285.
93. Prestegarden L, Enger PO. Cancer stem cells in the central nervous system - A critical review. Cancer Res 2010;70(21):8255-8. [Epub 2010 October 19].
94. LaBarge M.A. The difficulty of targeting cancer stem cell niches. Clin Cancer Res 2010, 16:3121-3129.
95. Butler J.M., Kobayashi H., Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 2010, 10:138-146.
96. Williams R.F., Sims T.L., Tracey L., Myers A.L., Ng C.Y., Poppleton H., et al. Maturation of tumor vasculature by interferon-beta disrupts the vascular niche of glioma stem cells. Anticancer Res 2010, 30:3301-3308.
97. McGee M.C., Hamner J.B., Williams R.F., Rosati S.F., Sims T.L., Ng C.Y., et al. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 2010, 76:1537-1545.
98. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196:254-265.
99. Ohtaki Y., Nagai I.G., Ashimine K., Kuwata S., Hishida T., Nishimura T., et al. Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol 2010, 5:1507-1515.
100. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330:827-830.
101. Barry-Hamilton V., Spangler R., Marshall D., McCauley S., Rodriguez H.M., Oyasu M., et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010, 16:1009-1017.